IRIS
RIMINI, MARGHERITA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.808
NA - Nord America 2.427
AS - Asia 2.394
SA - Sud America 462
AF - Africa 48
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.147
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.306
RU - Federazione Russa 1.609
SG - Singapore 822
CN - Cina 704
IT - Italia 406
BR - Brasile 380
RO - Romania 263
HK - Hong Kong 237
BD - Bangladesh 214
VN - Vietnam 214
FR - Francia 120
DE - Germania 101
GB - Regno Unito 72
SE - Svezia 72
CA - Canada 60
IN - India 51
MX - Messico 36
JP - Giappone 35
AR - Argentina 32
NL - Olanda 32
FI - Finlandia 27
AT - Austria 25
PL - Polonia 24
ZA - Sudafrica 22
ES - Italia 19
IQ - Iraq 14
TR - Turchia 14
ID - Indonesia 13
CL - Cile 9
CO - Colombia 9
EC - Ecuador 9
LT - Lituania 9
MA - Marocco 9
IE - Irlanda 8
AU - Australia 7
JM - Giamaica 7
MY - Malesia 7
NP - Nepal 7
PK - Pakistan 7
SA - Arabia Saudita 7
VE - Venezuela 7
EG - Egitto 6
AE - Emirati Arabi Uniti 5
BE - Belgio 5
PH - Filippine 5
UY - Uruguay 5
UZ - Uzbekistan 5
HN - Honduras 4
IR - Iran 4
PY - Paraguay 4
TW - Taiwan 4
UA - Ucraina 4
AZ - Azerbaigian 3
BO - Bolivia 3
CR - Costa Rica 3
KR - Corea 3
LB - Libano 3
SI - Slovenia 3
TT - Trinidad e Tobago 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
DZ - Algeria 2
IL - Israele 2
KG - Kirghizistan 2
KW - Kuwait 2
KZ - Kazakistan 2
MD - Moldavia 2
OM - Oman 2
SR - Suriname 2
SV - El Salvador 2
AL - Albania 1
BM - Bermuda 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CM - Camerun 1
CY - Cipro 1
GA - Gabon 1
GT - Guatemala 1
GY - Guiana 1
JO - Giordania 1
KE - Kenya 1
LK - Sri Lanka 1
MV - Maldive 1
NI - Nicaragua 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SX - ???statistics.table.value.countryCode.SX??? 1
TH - Thailandia 1
TN - Tunisia 1
Totale 8.147
Salva come PNG Salva come JPEG
Città #
Dallas 953
Singapore 490
Moscow 327
Ashburn 249
Hong Kong 229
San Jose 176
Beijing 158
New York 130
Ho Chi Minh City 84
Shanghai 78
Lauterbourg 77
Los Angeles 77
Milan 68
Hefei 64
Santa Clara 51
Rome 47
Hanoi 43
Orem 36
São Paulo 32
Tokyo 29
Munich 28
Boardman 27
Council Bluffs 24
Montreal 23
London 21
Nuremberg 21
Guangzhou 20
Naples 20
Poplar 20
Warsaw 20
Lawrence 19
Princeton 19
Stockholm 19
Denver 18
Cesano Boscone 17
Helsinki 17
Toronto 17
Chicago 16
Mexico City 16
Brooklyn 15
Buffalo 15
Frankfurt am Main 15
Vienna 15
Da Nang 14
Manchester 14
Rio de Janeiro 14
Chennai 13
Houston 13
Johannesburg 13
Romagnano Sesia 13
Atlanta 12
Phoenix 12
Biên Hòa 11
Boston 10
Monza 10
Lappeenranta 9
Dhaka 8
Haiphong 8
Secaucus 8
Shenzhen 8
Washington 8
Amsterdam 7
Bari 7
Bologna 7
Dublin 7
Philadelphia 7
Porto Alegre 7
Ankara 6
Bacoli 6
Belo Horizonte 6
Brasília 6
Changsha 6
Falkenstein 6
Mumbai 6
Newark 6
Padua 6
San Francisco 6
Tianjin 6
Buenos Aires 5
Catania 5
Columbus 5
Kuala Lumpur 5
Montevideo 5
New Delhi 5
North Bergen 5
Queens 5
Querétaro 5
Seattle 5
Tashkent 5
Verona 5
Assago 4
Brisbane 4
Brussels 4
Cairo 4
Calgary 4
Cape Town 4
Charlotte 4
Chengdu 4
Contagem 4
Duque de Caxias 4
Totale 4.246
Salva come PNG Salva come JPEG
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 430
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 420
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study 349
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 131
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 131
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 128
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 127
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents 120
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 117
Combined hepatocellular-cholangiocarcinoma: morpho-molecular updates and considerations 116
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 115
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 115
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 112
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 112
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 110
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 110
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 110
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 108
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 107
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 105
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 103
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis 103
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients 103
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 100
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 100
Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and 99mTc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization 90Y PET/CT 99
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? 99
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 99
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 98
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 97
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 94
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 90
Angiogenesis in biliary tract cancer: targeting and therapeutic potential 89
Cholangiocarcinoma: new perspectives for new horizons 88
The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: A Pilot Experience from Modena Cancer Center 85
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 83
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 83
Correction: Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and 99mTc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization 90Y PET/CT 82
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 82
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 81
The oncologic burden of residual disease in incidental gallbladder cancer: An elastic net regression model to profile high-risk features 80
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 80
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 78
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 75
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting 74
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 73
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma 73
Treatment options for advanced hepatocellular carcinoma: the potential of biologics 73
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 72
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience 71
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 71
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 71
Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index 71
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 70
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 70
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 69
Clinical implications of malnutrition in the management of patients with pancreatic cancer: Introducing the concept of the nutritional oncology board 69
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study 66
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 66
Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma 66
The prognostic value of the new combined hemo-eosinophil inflammation index (Hei index): A multicenter analysis of anal cancer patients treated with concurrent chemo-radiation 66
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib 63
Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis (Targeted Oncology, (2021), 16, 3, (401-410), 10.1007/s11523-021-00797-3) 63
Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population Study 62
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib 61
Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis 61
Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis 60
The Prognostic Role of Baseline Eosinophils in HPV-Related Cancers: a Multi-institutional Analysis of Anal SCC and OPC Patients Treated with Radical CT-RT 59
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 58
Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report 58
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study 58
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis 58
Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients 58
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib 58
Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib 57
Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases 57
Child Pugh and ALBI grade: past, present or future? 57
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study 56
Lenvatinib as a therapy for unresectable hepatocellular carcinoma 55
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 54
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation 53
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma 53
Response to letter entitled Re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 50
Viral Hepatitis in Western Patients with Advanced Intrahepatic Cholangiocarcinoma: Retrospective Assessment of Prevalence, Prognostic and Predictive Significance 50
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 49
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib 49
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy 44
Why does survival of hepatocellular carcinoma patients remain so low? Key stumbling blocks and questions in preclinical and clinical development 43
Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors? 41
Radial and Longitudinal Margins in Surgery of Perihilar Cholangiocarcinoma: When R1 Definition Is Associated with Different Prognosis 40
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies 39
Surgery for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: milestone changes in the last two decades potentially affecting current guidelines 39
External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study 37
Correction to: Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 35
Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study 32
Il trattamento del carcinoma squamocellulare cutaneo localmente avanzato e metastatico 28
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 22
Letter Re: Reflections on the MAGIC-D Prognostic Model in Advanced Biliary Tract Cancer 17
null 7
Comprehensive genetic analysis in biliary tract cancer: a prospective single-center experience 2
Totale 8.378
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.275
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.275
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202218 0 0 0 1 0 0 2 12 2 0 0 1
2022/2023118 42 20 4 1 1 22 7 7 8 2 1 3
2023/2024224 12 3 31 18 13 50 3 15 0 5 24 50
2024/20251.228 92 27 18 13 38 91 384 140 122 79 62 162
2025/20266.786 385 685 814 737 527 225 426 468 1.543 285 339 352
Totale 8.379